BRAF and neoplasm: More molecular targets such as anaplastic lymphoma kinase (ALK), ROS proto‐oncogene 1, receptor tyrosine kinase (ROS1), and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) have shown promising anti-tumor efficacy.